insights_auto
Why is ALKS down 2.01%?
Dive Deeperchevron_right
ALKS:NASDAQ
Alkermes Plc
$43.29
arrow_downward
-2.01%(-0.89) 1D
$43.29
0.00% (0.00)
bedtimeAfter hours
Closed: Sep 22, 4:00:01 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALKS...
Open
$44.39
High
$44.53
Low
$43.08
Mkt. cap
7.26B
Avg. vol.
1.64M
Volume
0.00
P/E ratio
112.48
52-wk high
$55.67
52-wk low
$26.99
EPS
$0.38
Beta
0.27
Shares outstanding
167.76M
No. of employees
2K
Open
$44.39
High
$44.53
Low
$43.08
Mkt. cap
7.26B
Avg. vol.
1.64M
Volume
0.00
P/E ratio
112.48
52-wk high
$55.67
52-wk low
$26.99
EPS
$0.38
Beta
0.27
Shares outstanding
167.76M
No. of employees
2K
News stories
From web sources and news partners
Psychiatric Times
·
13 hours ago
Positive Phase 1b Results Demonstrate Clinical Proof-of-Concept for ALKS 7290 in Adults With ADHD
Zacks
·
15 hours ago
Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290
Benzinga
·
17 hours ago
Meta To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Tuesday
Simply Wall Street
·
19 hours ago
What ALKS 7290 ADHD Trial Results Mean For Alkermes (ALKS) Stock
Profile
Alkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall. In September 2011 Alkermes, Inc. merged with Elan Drug Technologies, the former drug formulation and manufacturing division of Élan Corporation, plc. The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio. Wikipedia
About Alkermes Plc
CEORichard F. Pops | Richard F. Pops
Employees2.05K
Founded1987
Headquarters-
SectorBiotechnology
Websitealkermes.com